

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person* Engels John P <small>(Last) (First) (Middle)</small> C/O AXOGEN, INC., 13859 PROGRESS BOULEVARD, SUITE 100 <small>(Street)</small> ALACHUA, FL 32615 <small>(City) (State) (Zip)</small>	2. Date of Event Requiring Statement (Month/Day/Year) 09/30/2011	3. Issuer Name and Ticker or Trading Symbol AxoGen, Inc. [AXGN]	
		4. Relationship of Reporting Person(s) to Issuer <small>(Check all applicable)</small> <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) <div style="border: 1px solid black; padding: 2px; display: inline-block;">Vice President</div>	5. If Amendment, Date Original Filed(Month/Day/Year) 10/11/2011
6. Individual or Joint/Group Filing Check Applicable Line <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person			

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Employee Stock Option (right to buy)	06/07/2006	06/07/2016	Common Stock	3,727 (1) (2)	\$ 0.2683 (3) (4)	D	
Employee Stock Option (right to buy)	12/06/2007	12/06/2017	Common Stock	719 (1) (5)	\$ 0.2683 (3) (4)	D	
Employee Stock Option (right to buy)	11/18/2008	11/18/2018	Common Stock	406 (1) (6)	\$ 0.2683 (3) (4)	D	
Employee Stock Option (right to buy)	06/09/2010	06/09/2020	Common Stock	45,685 (1) (7)	\$ 0.2683 (3) (4)	D	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Engels John P C/O AXOGEN, INC. 13859 PROGRESS BOULEVARD, SUITE 100 ALACHUA, FL 32615			Vice President	

Signatures

/s/ John P. Engels	03/22/2012
<small>**Signature of Reporting Person</small>	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) These options vest semi-annually over four years from the date of grant.
- (2) All of these options have vested.
- (3) Amended to correct mistake in option exercise price after appropriate application of conversion ratio as explained in footnotes.

Pursuant to an Agreement and Plan of Merger, dated as of May 31, 2011, by and among LecTec Corporation ("LecTec"), Nerve Merger Sub Corp., a subsidiary of LecTec ("Merger Sub"), and AxoGen Corporation ("AC"), which the parties amended on June 30, 2011 and August 9, 2011 (as amended, the "Merger Agreement"), Merger Sub merged with and into AC, with AC continuing after the merger as the surviving corporation and a wholly owned subsidiary of LecTec (the "Merger"). The Merger was completed on September 30, 2011, and LecTec was renamed AxoGen, Inc. ("AxoGen"). In connection with the Merger, each share of AC common stock converted into 0.03727336 share of LecTec common stock at the effective time of the Merger. In connection with the Merger, each option to purchase shares of AC common stock was converted for an option to purchase 0.03727336 of a share of AxoGen common stock.

- (4) 629 options have vested, and 90 options are unvested.
- (5) 254 options have vested, and 152 options are unvested.
- (6) 11,421 options have vested, and 34,264 options are unvested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.